Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Colchicine Is a Competitive Antagonist at Human Recombinant γ-Aminobutyric AcidA Receptors

J. L. Weiner, A. V. Buhler, V. J. Whatley, R. A. Harris and T. V. Dunwiddie
Journal of Pharmacology and Experimental Therapeutics January 1998, 284 (1) 95-102;
J. L. Weiner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. V. Buhler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. J. Whatley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. A. Harris
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. V. Dunwiddie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Colchicine is an alkaloid that is used clinically in the treatment of arthritic gout. This potent microtubule disrupting agent has also been used extensively as an experimental tool in studies characterizing the role of the cytoskeleton in a variety of cellular processes. Colchicine has also been used as a selective neurotoxin and in animal models of Alzheimer’s disease and epilepsy. Although the mechanism(s) mediating the neurotoxic actions of colchicine have not been established, most studies have attributed these effects to its microtubule depolymerizing actions. Here we report another central nervous system action of colchicine, competitive antagonism of γ-aminobutyric acid (GABA)A receptor function. By use of a rapid drug perfusion system, colchicine (10–1000 μM) significantly inhibited GABA currents recorded from L(tk−) cells stably transfected with human α1β2γ2L GABAA receptor subunits. The inhibition was rapid and reversible, with 100 μM colchicine shifting the GABA EC50 from 2.5 to 5.1 μM with no effect on currents evoked by saturating concentrations of GABA. Colchicine also significantly inhibited binding of the competitive GABAAreceptor antagonist [3H]SR-95531. Other microtubule disrupting agents (10 μM vinblastine, 10 μg/ml nocodazole, 1 μM taxol) had no acute effects on GABA currents, nor did the inactive analog γ-lumicolchicine (100 μM). Moreover, pretreating cells with colchicine, vinblastine, nocodazole or taxol for 1 to 4 hr did not occlude the acute inhibitory action of colchicine. We conclude that, in addition to its well characterized effects on microtubule assembly, colchicine can also inhibit GABAA receptor function through a direct interaction with the receptor/ion channel complex.

Footnotes

  • Send reprint requests to: Jeff L. Weiner, Ph.D., Dept. of Pharmacology, Box C-236, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262.

  • ↵1 This research was supported by National Institutes of Health grants AA 05425 (J.L.W.), AA 03527 (T.V.D.) and by the Veterans Administration Medical Research Service.

  • Abbreviations:
    DMSO
    dimethyl sulfoxide
    EGTA
    ethylene glycol-O,O′-bis(2-aminoethyl)-N,N,N′,N′-tetraacetic acid
    HEPES
    N-[2-hydroxyethyl]piperazine-N′-[2-ethanesulfonic acid]
    GABA
    γ-aminobutyric acid
    SR-95531
    2-(3′-carbethoxy)-phenylpyridazinium bromide
    • Received July 15, 1997.
    • Accepted September 15, 1997.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 284, Issue 1
1 Jan 1998
  • Table of Contents
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Colchicine Is a Competitive Antagonist at Human Recombinant γ-Aminobutyric AcidA Receptors
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Colchicine Is a Competitive Antagonist at Human Recombinant γ-Aminobutyric AcidA Receptors

J. L. Weiner, A. V. Buhler, V. J. Whatley, R. A. Harris and T. V. Dunwiddie
Journal of Pharmacology and Experimental Therapeutics January 1, 1998, 284 (1) 95-102;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
OtherCELLULAR AND MOLECULAR PHARMACOLOGY

Colchicine Is a Competitive Antagonist at Human Recombinant γ-Aminobutyric AcidA Receptors

J. L. Weiner, A. V. Buhler, V. J. Whatley, R. A. Harris and T. V. Dunwiddie
Journal of Pharmacology and Experimental Therapeutics January 1, 1998, 284 (1) 95-102;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Antagonism of an Adenosine/ATP Receptor in FollicularXenopus Oocytes
  • Toxin and Subunit Specificity of Blocking Affinity of Three Peptide Toxins for Heteromultimeric, Voltage-Gated Potassium Channels Expressed in Xenopus Oocytes
  • Inhibition of Voltage-Dependent Sodium Channels by the Anticonvulsant γ-Aminobutyric Acid Type A Receptor Modulator, 3-Benzyl-3-Ethyl-2-Piperidinone
Show more CELLULAR AND MOLECULAR PHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics